FDA Releases New Guidance on Drug Development Tools - - BioPharm International

ADVERTISEMENT

FDA Releases New Guidance on Drug Development Tools


FDA has released guidance on the process for qualifying drug development tools (DDTs) intended for potential use, over time, in multiple drug development programs. Guidance for Industry and FDA Staff, Qualification Process for Drug Development Tools defines DDTs as methods, materials, or measures that aid drug development that include, but are not limited to, biomarkers, clinical outcome assessments (COAs), and animal models for drug development under the Animal Rule.

FDA provides a framework for interactions between the Center for Drug Evaluation and Research (CDER) and the submitter of the DDT for qualification. The guidance outlines the kinds of data that should be submitted to support qualification of a DDT. It also creates a process for CDER’s formal review of the data.

The guidance states, “Qualification does not pertain to the process for review of DDTs that are submitted as part of regulatory applications for a specific drug development program. Furthermore, this guidance does not address the evidentiary standards or performance requirements needed for purposes of qualification.”

FDA also released an attachment to the guidance on the qualification of exacerbations of chronic pulmonary disease tool.

Source: FDA.gov

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here